TrialThe Lancet. Oncology2015

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Jürg Bernhard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.